IFN, IL-1, IL-6, and complement factor 5a are all mediators that target the extreme inflammatory response that occurs after SARS-CoV-2 infection with the aim of avoiding organ damage (135–137) thus monoclonal antibodies aiming to block these factors, together with tyrosine kinase inhibitors are being used to block the cytokine storm-like response or their ability to avert pulmonary vascular leakage in people with COVID-19. Here, IL1B is linked to COVID-19.